Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer (NSCLC): A randomised trial of chemotherapy plus radiotherapy versus radiotherapy alone

Cancer Research UK (CRUK) (UK)0 个研究点目标入组 0 人开始时间: 2001年7月1日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Age 75 years or under
•2. Histologically or cytologically proven non-small cell lung cancer, ie adeno- squamous or large cell carcinoma
•3. Clinically or radiologically evaluable disease 4. Inoperable, but clinically limited stage disease
•5. WHO performance status of 0-2
•6. No previous chemotherapy or radiotherapy
•7. No metastatic disease, except ipsilateral stem cell factor (SCF) lymphadenopathy
•8. Normal renal function
•9. No other previous or concurrent malignancy, except cone biopsied carcinoma in-situ of the cervix and adequately treated basal cell carcinoma of the skin
•10. No pleural effusion or symptomatic superior vena cava obstruction
•11. No pre-existing severe impairment of lung function likely to prejudice the safe administration of the proposed radiotherapy
•12. No indication that protocol treatment would exacerbate a serious pre-existing medical condition

发起方

Cancer Research UK (CRUK) (UK)